Objective
HVC is a growing European medical problem here there is no effective long-term therapy. Mostly fatal, this infectious disease may be chronically carried by 5 million Europeans placing a huge burden on medical services and resources. Novel and effective antiviral therapies are therefore urgently needed. We use rational drug design to develop new drugs to combat HCV at a critical stage in its life cycle. Our dugs fit a specific target in the RNA structure, freezing its shape, it is no longer able to bind its native protein, and thus viral replication is inhibited. We will determine the 3D structure of the RNA target, design and make novel drugs, develop assays to measure inhibition of RNA function, and make through iterative cycles lead molecules. In collaboration withal pharmaceutical partner such drugs would be entered into a clinical evaluation programme. This research will benefit Europeans by producing novel therapies to this debilitating and often fatal disease.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
- medical and health sciencesbasic medicinemedicinal chemistry
- medical and health scienceshealth sciencesinfectious diseasesRNA viruseshepatitis C
- natural sciencesbiological sciencesbiochemistrybiomoleculesproteins
- natural sciencesbiological sciencesgeneticsRNA
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
CB1 6GB CAMBRIDGE
United Kingdom